232 related articles for article (PubMed ID: 16956823)
1. The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy.
Bataille R; Jégo G; Robillard N; Barillé-Nion S; Harousseau JL; Moreau P; Amiot M; Pellat-Deceunynck C
Haematologica; 2006 Sep; 91(9):1234-40. PubMed ID: 16956823
[TBL] [Abstract][Full Text] [Related]
2. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma.
Lin P; Owens R; Tricot G; Wilson CS
Am J Clin Pathol; 2004 Apr; 121(4):482-8. PubMed ID: 15080299
[TBL] [Abstract][Full Text] [Related]
3. CD28, a marker associated with tumoral expansion in multiple myeloma.
Robillard N; Jego G; Pellat-Deceunynck C; Pineau D; Puthier D; Mellerin MP; Barillé S; Rapp MJ; Harousseau JL; Amiot M; Bataille R
Clin Cancer Res; 1998 Jun; 4(6):1521-6. PubMed ID: 9626472
[TBL] [Abstract][Full Text] [Related]
4. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
Kara IO; Sahin B; Paydas S; Cetiner S
Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
[TBL] [Abstract][Full Text] [Related]
5. Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders.
Raja KR; Kovarova L; Hajek R
Br J Haematol; 2010 May; 149(3):334-51. PubMed ID: 20201947
[TBL] [Abstract][Full Text] [Related]
6. Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization.
Pellat-Deceunynck C; Barillé S; Puthier D; Rapp MJ; Harousseau JL; Bataille R; Amiot M
Cancer Res; 1995 Aug; 55(16):3647-53. PubMed ID: 7543019
[TBL] [Abstract][Full Text] [Related]
7. Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma.
Gupta R; Bhaskar A; Kumar L; Sharma A; Jain P
Am J Clin Pathol; 2009 Nov; 132(5):728-32. PubMed ID: 19846814
[TBL] [Abstract][Full Text] [Related]
8. Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma.
Liu D; Lin P; Hu Y; Zhou Y; Tang G; Powers L; Medeiros LJ; Jorgensen JL; Wang SA
J Clin Pathol; 2012 Sep; 65(9):823-9. PubMed ID: 22685235
[TBL] [Abstract][Full Text] [Related]
9. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
[TBL] [Abstract][Full Text] [Related]
10. [Detection of multiple myeloma cells using multicolor immunofluorescence and flow cytometry].
Tousková M; Maisnar V; Krejsek J; Kopecký O
Vnitr Lek; 1999 Dec; 45(12):708-12. PubMed ID: 10951845
[TBL] [Abstract][Full Text] [Related]
11. Low CD27 expression in plasma cell dyscrasias correlates with high-risk disease: an immunohistochemical analysis.
Morgan TK; Zhao S; Chang KL; Haddix TL; Domanay E; Cornbleet PJ; Arber DA; Natkunam Y
Am J Clin Pathol; 2006 Oct; 126(4):545-51. PubMed ID: 16938662
[TBL] [Abstract][Full Text] [Related]
12. Lack of CD27 in myeloma delineates different presentation and outcome.
Moreau P; Robillard N; Jégo G; Pellat C; Le Gouill S; Thoumi S; Avet-Loiseau H; Harousseau JL; Bataille R
Br J Haematol; 2006 Jan; 132(2):168-70. PubMed ID: 16398651
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneous expression of CD32 and CD32-mediated growth suppression in human myeloma cells.
Zheng X; Abroun S; Otsuyama K; Asaoku H; Kawano MM
Haematologica; 2006 Jul; 91(7):920-8. PubMed ID: 16818279
[TBL] [Abstract][Full Text] [Related]
14. [Preliminary study of immunophenotype of multiple myeloma cells].
Wang LL
Zhonghua Zhong Liu Za Zhi; 1993 Jul; 15(4):286-8. PubMed ID: 8174466
[TBL] [Abstract][Full Text] [Related]
15. Instability of immunophenotype in plasma cell myeloma.
Cao W; Goolsby CL; Nelson BP; Singhal S; Mehta J; Peterson LC
Am J Clin Pathol; 2008 Jun; 129(6):926-33. PubMed ID: 18480010
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy.
Mateo G; Montalbán MA; Vidriales MB; Lahuerta JJ; Mateos MV; Gutiérrez N; Rosiñol L; Montejano L; Bladé J; Martínez R; de la Rubia J; Diaz-Mediavilla J; Sureda A; Ribera JM; Ojanguren JM; de Arriba F; Palomera L; Terol MJ; Orfao A; San Miguel JF; ;
J Clin Oncol; 2008 Jun; 26(16):2737-44. PubMed ID: 18443352
[TBL] [Abstract][Full Text] [Related]
17. CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity.
Bataille R; Robillard N; Avet-Loiseau H; Harousseau JL; Moreau P
Haematologica; 2005 May; 90(5):706-7. PubMed ID: 15921396
[TBL] [Abstract][Full Text] [Related]
18. Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6.
Dezorella N; Pevsner-Fischer M; Deutsch V; Kay S; Baron S; Stern R; Tavor S; Nagler A; Naparstek E; Zipori D; Katz BZ
Exp Cell Res; 2009 Jul; 315(11):1904-13. PubMed ID: 19328780
[TBL] [Abstract][Full Text] [Related]
19. Normal and malignant human plasma cells: proliferation, differentiation, and expansions in relation to CD45 expression.
Pellat-Deceunynck C; Bataille R
Blood Cells Mol Dis; 2004; 32(2):293-301. PubMed ID: 15003821
[TBL] [Abstract][Full Text] [Related]
20. Six color flow cytometry detects plasma cells expressing aberrant immunophenotype in bone marrow of healthy donors.
Peceliunas V; Janiulioniene A; Matuzeviciene R; Griskevicius L
Cytometry B Clin Cytom; 2011 Sep; 80(5):318-23. PubMed ID: 21634008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]